Exencial Wealth Advisors LLC Sells 27,569 Shares of Medtronic plc (NYSE:MDT)

Exencial Wealth Advisors LLC lowered its holdings in Medtronic plc (NYSE:MDT - Free Report) by 15.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 148,858 shares of the medical technology company's stock after selling 27,569 shares during the quarter. Exencial Wealth Advisors LLC's holdings in Medtronic were worth $11,891,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Darwin Wealth Management LLC bought a new stake in Medtronic in the third quarter valued at $27,000. Stephens Consulting LLC lifted its position in shares of Medtronic by 145.7% in the 4th quarter. Stephens Consulting LLC now owns 344 shares of the medical technology company's stock worth $27,000 after purchasing an additional 204 shares during the period. J. Stern & Co. LLP bought a new stake in shares of Medtronic during the 3rd quarter valued at about $30,000. Fiduciary Advisors Inc. bought a new stake in shares of Medtronic during the 4th quarter valued at about $36,000. Finally, Kieckhefer Group LLC bought a new position in Medtronic in the fourth quarter worth about $40,000. 82.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Brett A. Wall sold 12,437 shares of the firm's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $1,119,330.00. Following the sale, the executive vice president now owns 40,979 shares of the company's stock, valued at $3,688,110. This trade represents a 23.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Medtronic Stock Down 0.6 %

Shares of MDT traded down $0.59 on Thursday, hitting $93.47. 951,289 shares of the stock traded hands, compared to its average volume of 6,011,587. Medtronic plc has a one year low of $75.96 and a one year high of $95.57. The company has a market capitalization of $119.88 billion, a PE ratio of 28.36, a P/E/G ratio of 2.22 and a beta of 0.84. The business has a 50 day simple moving average of $87.82 and a 200 day simple moving average of $87.68. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.39 and a current ratio of 1.90.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, topping analysts' consensus estimates of $1.36 by $0.03. The business had revenue of $8.29 billion during the quarter, compared to analyst estimates of $8.33 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. As a group, equities analysts forecast that Medtronic plc will post 5.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MDT shares. Sanford C. Bernstein increased their target price on Medtronic from $96.00 to $97.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 20th. Barclays increased their price objective on Medtronic from $105.00 to $109.00 and gave the stock an "overweight" rating in a report on Tuesday, November 26th. Royal Bank of Canada restated an "outperform" rating and set a $105.00 target price on shares of Medtronic in a report on Wednesday, February 19th. Citigroup upgraded shares of Medtronic from a "neutral" rating to a "buy" rating and increased their price target for the stock from $92.00 to $107.00 in a research note on Tuesday. Finally, Truist Financial dropped their price objective on shares of Medtronic from $93.00 to $89.00 and set a "hold" rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $96.07.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.